[21] are in vitro and do not establish clinical efficacy or safety in dystrophinopathy; therefore, any relevance to DMD should be interpreted as hypothesis-generating and supportive of the need for dedicated clinical studies and integrated public-health planning (vaccination, early respiratory assessment, and guideline-based respiratory management) for rare neuromuscular diseases [21,31,32,33]. The gene discussed is DMD; the disease is neuromuscular disease caused by qualitative or quantitative defects of dystrophin.